Last reviewed · How we verify
Rivaroxaban, dabigatran, apixaban, or edoxaban
Rivaroxaban, dabigatran, apixaban, or edoxaban is a Direct oral anticoagulant (DOAC) Small molecule drug developed by Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
These are direct oral anticoagulants (DOACs) that inhibit specific clotting factors to prevent blood clot formation.
These are direct oral anticoagulants (DOACs) that inhibit specific clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Rivaroxaban, dabigatran, apixaban, or edoxaban |
|---|---|
| Sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban, apixaban, and edoxaban are Factor Xa inhibitors that block the conversion of prothrombin to thrombin, while dabigatran is a direct thrombin inhibitor that prevents thrombin-mediated clot formation. All four drugs reduce the ability of blood to clot, thereby preventing thromboembolism in conditions such as atrial fibrillation and venous thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome (select agents)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Nausea
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (NA)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban, dabigatran, apixaban, or edoxaban CI brief — competitive landscape report
- Rivaroxaban, dabigatran, apixaban, or edoxaban updates RSS · CI watch RSS
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec portfolio CI
Frequently asked questions about Rivaroxaban, dabigatran, apixaban, or edoxaban
What is Rivaroxaban, dabigatran, apixaban, or edoxaban?
How does Rivaroxaban, dabigatran, apixaban, or edoxaban work?
What is Rivaroxaban, dabigatran, apixaban, or edoxaban used for?
Who makes Rivaroxaban, dabigatran, apixaban, or edoxaban?
What drug class is Rivaroxaban, dabigatran, apixaban, or edoxaban in?
What development phase is Rivaroxaban, dabigatran, apixaban, or edoxaban in?
What are the side effects of Rivaroxaban, dabigatran, apixaban, or edoxaban?
What does Rivaroxaban, dabigatran, apixaban, or edoxaban target?
Related
- Drug class: All Direct oral anticoagulant (DOAC) drugs
- Target: All drugs targeting Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)
- Manufacturer: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Deep vein thrombosis (DVT) treatment and prevention
- Indication: Drugs for Pulmonary embolism (PE) treatment and prevention
- Compare: Rivaroxaban, dabigatran, apixaban, or edoxaban vs similar drugs
- Pricing: Rivaroxaban, dabigatran, apixaban, or edoxaban cost, discount & access